Pre-open movers
U.S. stock futures traded lower in early pre-market trade. Data on personal income and consumer spending for April will be
released at 8:30 a.m. ET, while the S&P Corelogic Case-Shiller home price index for March is schedule for release at 9:00 a.m.
ET. The Conference Board’s Consumer Confidence Index for May will be released at 10:00 a.m. ET, while the Dallas Fed general
activity index for May will be released at 10:30 a.m. ET.
Futures for the Dow Jones Industrial Average dropped 35 points to 21,031, while the Standard & Poor’s 500 index futures fell
4.25 points to 2,409.50. Futures for the Nasdaq 100 index declined 5.75 points to 5,786.50.
Oil prices traded lower as Brent crude futures fell 0.92 percent to trade at $51.81 per barrel, while US WTI crude futures
dropped 0.50 percent to trade at $49.55 a barrel.
A Peek Into Global Markets
European markets were mostly lower today, with the Spanish Ibex Index dropping 0.22 percent, STOXX Europe 600 Index rising 0.04
percent and German DAX 30 index dropping 0.11 percent. The UK's FTSE index was trading lower by 0.43 percent, while French CAC 40
Index declined 0.58 percent.
In Asian markets, Japan’s Nikkei Stock Average fell 0.02 percent, Hong Kong’s Hang Seng Index rose 0.24 percent, China’s
Shanghai Composite Index gained 0.07 percent and India’s BSE Sensex rose 0.16 percent.
Broker Recommendation
Analysts at Wedbush downgraded Buffalo Wild Wings (NASDAQ: BWLD) from Neutral to Underperform.
Buffalo Wild Wings shares fell 1.47 percent to close at $151.00 on Friday.
Breaking news
-
Loxo Oncology Inc (NASDAQ: LOXO) disclosed the
FDA clearance for INDA for LOXO-195.
-
Patriot National Inc (NYSE: PN) announced plans to
explore strategic alternatives for the company.
-
Array Biopharma Inc (NASDAQ: ARRY) and
Bristol-Myers Squibb Co (NYSE: BMY) announced plans
to collaborate on Array's MEK inhibitor.
-
Merck & Co., Inc. (NYSE: MRK) reported that it has
received the FDA approval of ISENTRESS for the treatment of HIV-1.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.